WCLC 2022 | Detectability of uncommon EGFR mutations in NSCLC: NGS versus PCR
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, provides an overview on a retrospective analysis on EGFR testing for uncommon mutations. 18 months of prior genotyping data from the Royal Marsden NHS Foundation Trust was investigated on uncommon EGFR mutations in EGFR exons 18-21 in NSCLC. Within the 18 month period, 45 patients were identified with uncommon EGFR mutations via next-generation sequencing (NGS). The patient samples were analyzed via PCR, which missed 30% of the uncommon EGFR mutations that were detected by NGS. Thus, 30% of the uncommon mutations would have not been detected by the frequently used PCR-based assays, demonstrating NGS to be superior to PCR-based testing in identifying uncommon EGFR mutations. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
Transcript (edited for clarity)
Here at the World Lung Cancer Congress 2022 in Vienna, our group presented data on the EGFR testing for uncommon mutations using retrospective analysis of our labs genotyping outputs. We looked at the last 18 months of EGFR genotyping looking at exons 18 to 21. Looking, specifically, for the EGFR uncommon mutations. We identified 45 patients during this period of time, meaning they’re not that uncommon...
Here at the World Lung Cancer Congress 2022 in Vienna, our group presented data on the EGFR testing for uncommon mutations using retrospective analysis of our labs genotyping outputs. We looked at the last 18 months of EGFR genotyping looking at exons 18 to 21. Looking, specifically, for the EGFR uncommon mutations. We identified 45 patients during this period of time, meaning they’re not that uncommon. And we looked to see which of these 45 mutations would’ve been picked up by PCR-based assays, such as Cobas or Idylla. And about 30% of these EGFR uncommon mutations would not have been picked up by a PCR-based assay, such as Cobas or Idylla. Therefore, I think our data demonstrates that NGS is superior to PCR-based testing to identify EGFR uncommon mutations. And that may have clinical impact as many of the mutations were identified clinically impacted on the decision making for these patients.
Read more...
